CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH

(2019) Zobair Younossi et al.   JOURNAL OF HEPATOLOGY

FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver

(2018) Romeo Papazyan et al.   JOURNAL OF LIPID RESEARCH

The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement

(2017) Vasilios G. Athyros et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013

(2017) Joseph A. Salami et al.   JAMA Cardiology

Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World

(2016) Mehmet Sayiner et al.   Clinics in Liver Disease

Clinical guidelines of non-alcoholic fatty liver disease: A systematic review

(2016) Jin-Zhou Zhu et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2015) Sumio Watanabe et al.   JOURNAL OF GASTROENTEROLOGY

LP18 : Obeticholic acid for NASH: benefits in a high risk subgroup and the effects of concomitant statin use

(2015) B. Neuschwander-Tetri et al.   JOURNAL OF HEPATOLOGY

A Comparison of the Mouse and Human Lipoproteome: Suitability of the Mouse Model for Studies of Human Lipoproteins

(2015) Scott M. Gordon et al.   JOURNAL OF PROTEOME RESEARCH

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

(2013) Len Verbeke et al.   HEPATOLOGY

Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice

(2013) Thomas Gautier et al.   JOURNAL OF LIPID RESEARCH

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Risk factors for hepatic decompensation in patients with primary biliary cirrhosis

(2013) Tian-Yan Shi   WORLD JOURNAL OF GASTROENTEROLOGY

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

(2012) Naga Chalasani et al.   HEPATOLOGY

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

(2011) G. Vernon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

(2011) Michael R. Charlton et al.   GASTROENTEROLOGY

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

(2010) Vasilios G Athyros et al.   LANCET

Statins in the Treatment of Dyslipidemia in the Presence of Elevated Liver Aminotransferase Levels: A Therapeutic Dilemma

(2010) Rossana M. Calderon et al.   MAYO CLINIC PROCEEDINGS

The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis

(2009) B. Cariou   DIABETES & METABOLISM

Identification of Novel Pathways That Control Farnesoid X Receptor-mediated Hypocholesterolemia

(2009) Yanqiao Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

(2009) Sabrina Cipriani et al.   JOURNAL OF LIPID RESEARCH

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

(2009) Philippe Lefebvre et al.   PHYSIOLOGICAL REVIEWS